Correction of a stress response including in the field of oncology is the most important task, since it has a significant effect on the outcome of surgical treatment. The solution of this problem can be facilitated by modern equipment of operating rooms, reduction of traumatism and invasiveness of interventions, optimization of preoperative preparation of a patient, new methods of anesthesia, analgesia and patient management in the postoperative period. On the other hand an approach, which is focused only on reducing the traumatic nature of surgical intervention, cannot be the main one in the concept of surgery for malignant tumors.

This review is devoted to the urgent problem of modern oncology - combined treatment of locally advanced lung cancer with neoadjuvant chemotherapy, chemoradiation, targeted therapy. Literature data on the influence of various variants of neoadjuvant therapy on the development of postoperative bronchopleural complications, risk factors, methods of their prevention are analyzed in detail. The role of primary and secondary plastics of the stump of the main bronchus, tracheobronchial anastomoses with various autoflaps is highlighted. The article analyzes the data of large meta-analyzes and works originating from specialized clinics dealing with this problem.

A patient with lung cancer carrying ROS1 translocation was treated by crizotinib and then subjected to surgery. Morphological analysis revealed pathologic complete response in surgically removed tissues, while PCR test provided convincing evidence for the presence of residual tumor cells. PCR analysis of lung cancer specific gene translocations allows carrying out highly sensitive and reliable monitoring of tumor disease during the course of treatment.

The individualization of cytostatic agent dose is an actual problem in isolated lung chemoperfusion (ILP). Hitherto it has been carried out according to anthropometric data, in particular, the surface area of the body. A biophysical model of ILP based on diffusion cisplatin transfer in the lung is proposed. The model indicates to get the individual drug dose according to physical lung volume, which can be measured by CT-volumetry. Cisplatin pharmacokinetics and model compliance with actual data are considered on the material of 28 ILP. Estimates of lung interstitial and vascular space volumes and diffusion characteristic of capillary membrane are obtained.

The analysis of long-term results of surgical treatment of 198 patients with non-small cell lung cancer (NSCLC) I -III stages. Bronchoplasty (BP) interventions were performed in 99 cases, the control group comprised 99 patients after pneumonectomies (PE) corresponding to the main prognostic criteria for patients after BP interventions. A 1-year, 3-year and 5-year observed survival rates of patients were 87.7%, 56.2% and 44.6% after BP versus 82.8%, 54.6% and 35.9% after PE, respectively. A 1-year, 3-year and 5-year disease-free survival in the BP group was 87.9%, 64.2% and 52.3% versus 88.1%, 61.6% and 37.9% in the PE group. The median of overall and disease-free survival was 51.4 and 55.2 months in the BP group versus 46.2 and 41.0 months in the PE group, respectively.